

## **Clinical Policy: Insulin Infusion Pump (Omnipod, Omnipod DASH)**

Reference Number: CP.PHAR.420

Effective Date: 04.23.19

Last Review Date: 05.20

Line of Business: Commercial, Medicaid, HIM-Medical Benefit

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

The following are continuous insulin delivery systems requiring prior authorization: Omnipod<sup>®</sup> Insulin Management System and Omnipod DASH<sup>™</sup> Insulin Management System.

### **FDA Approved Indication(s)**

Omnipod Insulin Management System and Omnipod DASH Insulin Management System:

- Intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin.

#### Omnipod Insulin Management System

- Components: 1) Adhesive disposable pump (Pod), 2) handheld Personal Diabetes Manager (PDM) device with built-in Abbott FreeStyle blood glucose meter (BGM)
  - Abbott FreeStyle test strips and control solution are used with the Abbott FreeStyle BGM for quantitative measurement of blood glucose (BG) in fresh whole capillary blood from the finger, upper arm and palm.\*
- Connectivity: Wireless radiofrequency communication between the Pod and PDM-BGM device.\*\*
- User guide and related resources: <https://www.myomnipod.com/podder-support>

#### Omnipod DASH Insulin Management System

- Components: 1) Adhesive disposable pump (DASH Pod), 2) handheld DASH PDM device, 3) compatible Contour<sup>®</sup> Next One BGM
  - Contour Next test strips and control solution are used with the Contour Next One BGM for quantitative measurement of BG in fresh capillary whole blood drawn from the fingertips or palm.\*
- Connectivity: Wireless Bluetooth communication between the DASH Pod, DASH PDM, Contour Next BGM and, if desired, an iPhone.\*\*
- User guide and related resources: <https://www.myomnipod.com/DASH>

*\*The Abbott FreeStyle and Contour Next One BGMs are intended for single-patient use and should not be shared. The BGMs should not be used for the diagnosis of or screening for diabetes or for neonatal use.*

*\*\* Data may be uploaded to Insulet provided Glooko<sup>®</sup> software allowing sharing with caregivers and providers and access from anywhere.*

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Omnipod and Omnipod DASH are **medically necessary** when the following criteria are met:

**I. Initial Approval Criteria**

**A. Diabetes Mellitus** (must meet all):

1. Diagnosis of diabetes mellitus (*including but not limited to type 1, type 2, and gestational diabetes*);
2. Prescribed by or in consultation with an endocrinologist;
3. Member has utilized one of the following insulin administration methods for at least the last 6 months (a or b):
  - a. Use of an insulin pump (*see Appendix B for examples of insulin pumps*);
  - b. Multiple daily insulin injections (meets i and ii):
    - i. Administration of at least 3 daily injections of a basal and bolus insulin regimen (*see Appendix B for examples of basal [intermediate- or long-acting] and bolus [short- or rapid-acting] insulin*);
    - ii. History of suboptimal blood sugar control despite appropriate management - examples of suboptimal control include, but are not limited to, any of the following (a-f):
      - a) Repeated hypoglycemic events [BG < 70 mg/dL];
      - b) Repeated episodes of diabetic ketoacidosis;
      - c) Wide blood sugar excursions;
      - d) Hypoglycemia unawareness;
      - e) Glycosylated hemoglobin level [HbA1c] ≥ 7.0;
      - f) “Dawn phenomenon” with fasting blood sugars repeatedly > 200 g/dL;
4. Member has monitored blood glucose ≥ 4 times a day for at least the last 6 months;
5. Member or caregiver has completed a physician-directed comprehensive diabetes management program;
6. Request meets both of the following (a and b):
  - a. Number of Pods does not exceed 10 per month;\*
  - b. Number of devices does not exceed one per warranty period (four years).

*\*For requests exceeding 10 Pods per month, a clinical rationale with documentation supports the higher quantity.*

**Approval duration:**

**Medicaid/HIM** – Pods (6 months); device (initial and then once every 4 years)

**Commercial** – Pods (6 months or to the member’s renewal date, whichever is longer); device (initial and then once every 4 years)

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Diabetes Mellitus (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Request is for continuing use of the same Omnipod device (*if switching between the Omnipod and Omnipod DASH devices, please refer to the initial criteria*);
3. Member is responding positively to therapy and is adherent to provider follow-up visits and training;
4. Request meets both of the following (a and b):
  - a. Number of Pods does not exceed 10 per month;\*
  - b. Number of devices does not exceed one per warranty period (four years).

*\*For requests exceeding 10 Pods per month, a clinical rationale with documentation supports the higher quantity.*

#### Approval duration:

**Medicaid/HIM** – Pods (12 months); device (initial and then once every 4 years)

**Commercial** – Pods (6 months or to the member's renewal date, whichever is longer); device (initial and then once every 4 years)

### B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less);** or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

## IV. Appendices/General Information

### Appendix A: Abbreviation/Acronym Key

BGM: blood glucose meter

CSII: continuous subcutaneous insulin infusion

FDA: Food and Drug Administration

MDI: multiple daily doses of insulin

PDM: Personal Diabetes Manager

Pod: tubeless insulin pump

T1DM: type 1 diabetes mellitus

T2DM: type 2 diabetes mellitus

### Appendix B: Therapeutic Alternatives

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<p><b>INSULIN PUMPS</b></p> <p><u>With tubing:</u></p> <ul style="list-style-type: none"> <li>• MiniMed™ System (530G, 630G, 670G)</li> <li>• MiniMed™ Paradigm Revel™</li> </ul> <p><u>Without tubing:</u></p> <ul style="list-style-type: none"> <li>• V-Go® 20, 30, 40</li> </ul>	Varies	Varies
<p><b>INSULIN</b></p> <p><b>Human Insulin</b></p> <p><u>Short-acting:</u></p> <ul style="list-style-type: none"> <li>• Regular insulin (HumuLIN® R U-500, HumuLIN® R U-500 KwikPen®, HumuLIN® R [OTC], NovoLIN® R ReliOn [OTC], NovoLIN® R [OTC])</li> </ul> <p><u>Intermediate-acting:</u></p> <ul style="list-style-type: none"> <li>• Insulin NPH (HumuLIN® N KwikPen® [OTC], HumuLIN® N [OTC], NovoLIN® N ReliOn [OTC], NovoLIN® N [OTC])</li> </ul> <p><u>Intermediate-acting and short-acting combinations:</u></p> <ul style="list-style-type: none"> <li>• Insulin NPH and regular insulin (HumuLIN® 70/30, HumuLIN® 70/30 KwikPen®, NovoLIN® 70/30)</li> </ul> <p><b>Insulin Analogs</b></p> <p><u>Rapid-acting</u></p> <ul style="list-style-type: none"> <li>• Insulin glulisine (Apidra, Apidra SoloStar®)</li> <li>• Insulin lispro (Admelog, Admelog SoloStar®, HumaLOG®, HumaLOG Junior KwikPen®, HumaLOG KwikPen®,</li> <li>• Insulin aspart (Fiasp®, Fiasp FlexTouch®, NovoLOG®, NovoLOG FlexPen®, NovoLOG PenFill®)</li> </ul> <p><u>Intermediate-acting and short-acting combinations:</u></p> <ul style="list-style-type: none"> <li>• Insulin aspart protamine and insulin aspart (NovoLOG Mix® 70/30, NovoLOG Mix 70/30 FlexPen®)</li> <li>• Insulin lispro protamine and insulin lispro (HumaLOG Mix®, HumaLOG Mix® 50/50, HumaLOG Mix 50/50 KwikPen®, HumaLOG Mix® 75/25, HumaLOG Mix 75/25 KwikPen®)</li> </ul> <p><u>Long-acting</u></p> <ul style="list-style-type: none"> <li>• Insulin glargine (Basaglar KwikPen®, Lantus®, Lantus SoloStar®, Toujeo Max SoloStar®, Toujeo SoloStar®)</li> <li>• Insulin detemir (Levemir®, Levemir FlexTouch®)</li> <li>• Insulin degludec (Tresiba®, Tresiba FlexTouch®)</li> </ul>	Varies	Varies

*Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): Omnipod and Omnipod DASH Insulin Management Systems are not recommended for people who are:
  - Unable to perform at least 4 blood glucose tests per day
  - Unable to maintain contact with their healthcare provider
  - Unable to use the System according to instructions
- Boxed warning(s): none reported

**V. Dosage and Administration**

Drug Name	Dosing Regimen*	Maximum Dose
<p>Omnipod Insulin Management System  <i>See User Guides for more information - available at <a href="https://www.myomnipod.com/podder-support">https://www.myomnipod.com/podder-support</a></i></p> <p>Omnipod DASH Insulin Management System  <i>See User Guides for more information - available at <a href="https://www.myomnipod.com/DASH">https://www.myomnipod.com/DASH</a></i></p>	<ul style="list-style-type: none"> <li>• Initial Omnipod and Omnipod DASH System use               <ul style="list-style-type: none"> <li>○ Provider recommends initial program settings and meets with patient and Omnipod System Trainer to program the PDM device and first Pod.</li> </ul> </li> <li>• Filling the Pod               <ul style="list-style-type: none"> <li>○ The Pod is filled with insulin FDA approved for insulin pumps (i.e., the following rapid-acting U100 insulin analogs: insulin glulisine (Apidra), insulin lispro (Admelog, HumaLOG), insulin aspart (NovoLOG)).</li> <li>○ Pod capacity accommodates 85 to 200 units of insulin depending on patient need (<i>for initial programming, each Pod must be filled with at least 85 units of insulin</i>).</li> </ul> </li> <li>• Pod priming               <ul style="list-style-type: none"> <li>○ The PDM device and Pod are placed next to each other so that the PDM may prime the Pod.</li> </ul> </li> <li>• Pod placement               <ul style="list-style-type: none"> <li>○ For site selection, see User Guides.</li> </ul> </li> <li>• Pod activation               <ul style="list-style-type: none"> <li>○ The Pod features an insulin-providing cannula that inserts automatically with the press of an “activate” button on the PDM device.</li> </ul> </li> <li>• Pod replacement               <ul style="list-style-type: none"> <li>○ The Pod may remain on the skin from 1 to 3 days after which a new Pod should be filled, primed, applied, and activated.</li> </ul> </li> </ul>	<p>200 units per day (1 Pod)</p>

*\*The dosing regimen applies to the Omnipod and Omnipod DASH systems; however, each system’s Pods and devices are not interchangeable.*

**VI. Product Availability**

Drug Name	Availability
Omnipod Insulin Management System <i>All Omnipod components (Pod, PDM, built-in BGM) have wireless radiofrequency connectivity that is not compatible with smartphones.</i>	<ul style="list-style-type: none"> <li>● Omnipod Pack 5, 10 (packs of 5 or 10 Pods)</li> <li>● Starter Kit (PDM device with built-in FreeStyle BGM)*</li> </ul> <hr/> <i>*The built-in FreeStyle BGM must be used with Abbott FreeStyle test strips and control solution; however, patients may choose to use other blood glucose testing methods with manual entry into the PDM device.</i>
Omnipod DASH Insulin Management System <i>All Omnipod DASH components (Pod, PDM, compatible BGM) have Bluetooth connectivity that is compatible with the iPhone.</i>	<ul style="list-style-type: none"> <li>● Omnipod Pack 5 (packs of 5 Pods)</li> <li>● Starter Kit (PDM DASH device plus a separate but compatible Contour<sup>®</sup> Next One BGM)*</li> </ul> <hr/> <i>*The compatible Contour Next One BGM must be used with Ascensia Contour<sup>®</sup> Next test strips and control solution; however, patients may choose to use other blood glucose testing methods with manual entry into the PDM device.</i>

**VII. References**

1. Omnipod Insulin Management System and Omnipod DASH Insulin Management System 510(k) summary, No. K192659. Acton, MA: Insulet Corporation; October 2019. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf19/K192659.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192659.pdf). Accessed February 10, 2020.
2. Omnipod Insulin Management System and Omnipod DASH Insulin Management System 510(k) summary, No. K182630. Acton, MA: Insulet Corporation; January 2019. Available at: [https://www.accessdata.fda.gov/cdrh\\_docs/pdf18/K182630.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf18/K182630.pdf). Accessed March 25, 2019.
3. Omnipod Insulin Management System User Guide PDM Model UST400. Rev B September 2017. Available at: <https://www.myomnipod.com/podder-support>. Accessed February 10, 2020.
4. Lexicomp Online, Insulin Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2020; February 10, 2020.

**Omnipod Literature**

5. Omnipod Insulin Management System. Podder’s Handbook User Guide. Available at <https://www.myomnipod.com/sites/default/files/inline-files/17845-5A%20Guide%2C%20Eros%20US%20User%20Guide%20Rev%20B%20-%20View.pdf>. Accessed February 10, 2020.
6. Omnipod DASH Insulin Management System. Podder Resource Guide. Available at [https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW%20Rev%20B\\_USA%20DASH%20User%20Guide.pdf](https://www.myomnipod.com/sites/default/files/media/documents/18296-ENG-AW%20Rev%20B_USA%20DASH%20User%20Guide.pdf). Accessed February 20, 2020.
7. Layne JE, Parkin CG, Zisser H. Efficacy of the Omnipod Insulin Management System on
8. glycemic control in patients with type 1 diabetes previously treated with multiple daily injections or continuous subcutaneous insulin infusion. *J Diabetes Sci Technol.* 2016;10(5):1130-1135.
9. Layne JE, Parkin CG, Zisser H, et al. Efficacy of a tubeless patch pump in patients with type 2 diabetes previously treated with multiple daily injections. *J Diabetes Sci Technol.* 2017;11(1):178-179.

10. Ly TT, Layne JE, Huyett LM, et al. Novel Bluetooth-enabled tubeless insulin pump: innovating pump therapy for patients in the digital age. *J Diabetes Sci Technol.* 2019;13(1):20-26.

***Automated Insulin Delivery***

11. Diabetes technology: Standards of medical care in diabetes. American Diabetes Association. *Diabetes Care* 2019 Jan; 42 (Supplement 1): S71-S80. <https://doi.org/10.2337/dc19-S007>.
12. Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2018 position statement on integration of insulin pumps and continuous glucose monitoring in patients with diabetes mellitus. *Endocrine Practice*; March 2018; 24(3): 302-308.
13. Peters AL, Ahmann AJ, Hirsch IB, et al. Advances in glucose monitoring and automated insulin delivery: supplement to Endocrine Society clinical practice guidelines. *J Endocr Soc*; October 5 2018; 2(11): 1214-1225.

***Diabetes and Pregnancy***

14. Blumer I, Hadar E, Hadden DR, et al. Diabetes and Pregnancy: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* November 2013; 98(11): 4227-49.
15. Guideline for detection and management of diabetes in pregnancy. Joslin Diabetes Center and Joslin Clinic. November 10, 2016, January 11, 2107. Available at [https://www.joslin.org/Pregnancy-Guidelines\\_11-13-2016\\_corrected\\_1-11-2017.pdf](https://www.joslin.org/Pregnancy-Guidelines_11-13-2016_corrected_1-11-2017.pdf). Accessed April 22, 2019.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description*
A9274	External ambulatory insulin delivery system (Pod)
E0784	External ambulatory infusion pump, insulin (PDM device)

\*The codes apply to the Omnipod System only; they do not apply to the Omnipod DASH System.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created.	04.23.19	05.19
2Q 2020 annual review: no significant changes; references reviewed and updated.	02.11.20	05.20

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and

accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.



©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.